Find, compare & contact
Clofibride
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Clofibride API 26717-47-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Clofibride. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Clofibride
- Synonyms:
- Clofibrida , Clofibridum
- Cas Number:
- 26717-47-5
- DrugBank number:
- DB13849
- Unique Ingredient Identifier:
- 0S9SLS3L93
General Description:
Clofibride is a chemical compound identified by the CAS number 26717-47-5. It is known for its distinct pharmacological properties and applications.
Classification:
Clofibride belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative, classified under the direct parent group Phenoxyacetic acid derivatives. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Phenoxyacetic acid derivatives subclass.
Categories:
Clofibride is categorized under the following therapeutic classes: Acids, Acyclic, Agents Causing Muscle Toxicity, Benzene Derivatives, Butyrates, Clofibric Acid, Ethers, Fibric Acids, Isobutyrates, Lipid Modifying Agents, Lipid Modifying Agents, Plain, Lipid Regulating Agents, Phenols, Phenyl Ethers. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Clofibride is a type of Lipid-lowering agents
Lipid-lowering agents are a category of pharmaceutical active ingredients (APIs) that are widely used in the treatment of hyperlipidemia, a condition characterized by elevated levels of lipids (such as cholesterol and triglycerides) in the blood. These agents play a crucial role in managing lipid abnormalities and reducing the risk of cardiovascular diseases.
One of the most commonly prescribed lipid-lowering agents is statins. Statins work by inhibiting an enzyme called HMG-CoA reductase, which is responsible for the production of cholesterol in the liver. By blocking this enzyme, statins effectively lower cholesterol levels in the bloodstream.
Another class of lipid-lowering agents is fibric acid derivatives, which primarily target triglyceride levels. These agents activate a nuclear receptor known as PPAR-alpha, which regulates lipid metabolism. By activating PPAR-alpha, fibric acid derivatives enhance the breakdown of triglycerides and increase the elimination of fatty acids from the bloodstream.
Additionally, bile acid sequestrants are often used as lipid-lowering agents. These agents bind to bile acids in the intestine, preventing their reabsorption. As a result, the liver utilizes more cholesterol to produce new bile acids, leading to a decrease in circulating cholesterol levels.
Lipid-lowering agents are available in various formulations, including tablets, capsules, and suspensions, allowing for convenient administration. They are usually prescribed alongside lifestyle modifications, such as dietary changes and regular exercise, to optimize the management of hyperlipidemia.
It is important to note that the use of lipid-lowering agents should be under the supervision of a healthcare professional, as they may have potential side effects and interactions with other medications. Proper monitoring of lipid levels and regular follow-up visits are essential for ensuring the effectiveness and safety of these pharmaceutical agents.
